Literature DB >> 22422664

Cardiac sympathetic activation in patients with pulmonary arterial hypertension.

Susanna Mak1, Klaus K Witte, Abdul Al-Hesayen, John J Granton, John D Parker.   

Abstract

Patients with congestive heart failure (CHF) due to left ventricular (LV) dysfunction have sympathetic activation specifically directed to the myocardium. Although pulmonary arterial hypertension (PAH) is associated with increased systemic sympathetic activity, its impact on sympathetic drive to ventricular myocardium is unknown. Fifteen patients with PAH (9 women; 54 ± 12 years) were studied: 10 with idiopathic PAH and 5 with a connective tissue disorder. We measured hemodynamics, as well as radiolabeled and endogenous concentrations of arterial and coronary sinus norepinephrine (NE). These measures were repeated after inhaled nitric oxide (NO). Measurement of transcardiac NE concentrations and the cardiac extraction of radiolabeled NE allowed calculation of the corrected transcardiac gradient of NE (CTCG of NE). Comparative data were collected from 15 patients (9 women: 55 ± 12 yr) with normal LV function and 15 patients with CHF (10 women; 53 ± 12 yr). PAH patients had elevated arterial NE concentrations compared with those with normal LV function but were similar to those with CHF. The CTCG of NE was higher in those with PAH than in the normal LV group (3.6 ± 2.2 vs. 1.5 ± 0.9 pmol/ml; P < 0.01) but similar to that seen in those with CHF (3.3 ± 1.4; P = NS). Inhaled NO, which reduced pulmonary artery pressure and increased cardiac output, had no effect on cardiac sympathetic activity. Therefore, cardiac sympathetic activation occurs in PAH. The mechanism of this activation remains uncertain but does not involve elevations in left heart filling pressure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22422664     DOI: 10.1152/ajpregu.00652.2011

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  20 in total

Review 1.  The adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 Grover Conference series).

Authors:  Michael R Bristow; Robert A Quaife
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

Review 2.  Neurohormonal modulation as therapeutic avenue for right ventricular dysfunction in pulmonary artery hypertension: till the dawn, waiting.

Authors:  Roy Emanuel; Astha Chichra; Nirav Patel; Thierry H Le Jemtel; Abhishek Jaiswal
Journal:  Ann Transl Med       Date:  2018-08

3.  Sleep disordered breathing in group 1 pulmonary arterial hypertension.

Authors:  Milan Minic; John T Granton; Clodagh M Ryan
Journal:  J Clin Sleep Med       Date:  2014-03-15       Impact factor: 4.062

4.  Severity of arterial and chronic thromboembolic pulmonary hypertension is associated with impairment of heart rate turbulence.

Authors:  Piotr Bienias; Maciej Kostrubiec; Zuzanna Rymarczyk; Dariusz Korczak; Michał Ciurzyński; Marcin Kurzyna; Adam Torbicki; Anna Fijałkowska; Piotr Pruszczyk
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-06-05       Impact factor: 1.468

5.  Variability of Myocardial Repolarization in Pediatric Patients with a Ventricular Septal Defect.

Authors:  Hidetoshi Uchida; Miki Nishio; Yumi Omeki; Yuka Takeuchi; Rina Nagata; Shota Oikawa; Arisa Nagatani; Yoshihiko Eryu; Tadayoshi Hata; Tetsushi Yoshikawa
Journal:  Pediatr Cardiol       Date:  2016-08-23       Impact factor: 1.655

Review 6.  Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension.

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Circulation       Date:  2015-06-09       Impact factor: 29.690

7.  Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension.

Authors:  Omar A Minai; Quyen Nguyen; Srinivas Mummadi; Esteban Walker; Kevin McCarthy; Raed A Dweik
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

8.  Valsalva Maneuver in Pulmonary Arterial Hypertension: Susceptibility to Syncope and Autonomic Dysfunction.

Authors:  Philip L Mar; Victor Nwazue; Bonnie K Black; Italo Biaggioni; André Diedrich; Sachin Y Paranjape; James E Loyd; Anna R Hemnes; Ivan M Robbins; David Robertson; Satish R Raj; Eric D Austin
Journal:  Chest       Date:  2016-01-13       Impact factor: 9.410

9.  Involvement of Neuroinflammation in the Pathogenesis of Monocrotaline-Induced Pulmonary Hypertension.

Authors:  Ravindra K Sharma; Aline C Oliveira; Seungbum Kim; Katya Rigatto; Jasenka Zubcevic; Anandharajan Rathinasabapathy; Ashok Kumar; Joseph J Lebowitz; Habibeh Khoshbouei; Gilberto Lobaton; Victor Aquino; Elaine M Richards; Michael J Katovich; Vinayak Shenoy; Mohan K Raizada
Journal:  Hypertension       Date:  2018-04-30       Impact factor: 10.190

10.  Increased myocardial oxygen consumption rates are associated with maladaptive right ventricular remodeling and decreased event-free survival in heart failure patients.

Authors:  Ali Ahmadi; Jennifer M Renaud; Steven Promislow; Ian G Burwash; Girish Dwivedi; Ran Klein; Jason G E Zelt; Robert A deKemp; Rob S Beanlands; Lisa M Mielniczuk
Journal:  J Nucl Cardiol       Date:  2020-05-07       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.